Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 566658

Next Previous
Search
Drug Profile

SAR 566658

Alternative Names: Anti-CA6-antibody-drug-conjugate; Anti-CA6-DM4-immunoconjugate-SAR566658; huDS6-DM4; SAR-566658

Latest Information Update: 15 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; Sanofi
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Triple negative breast cancer

Most Recent Events

  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 08 Sep 2021 Discontinued - Phase-II for Triple negative Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, France, Belgium, Czech Republic, Italy, Netherlands (IV) (NCT02984683) (EudraCT2016-001962-27)
  • 08 Sep 2021 No development reported - Phase-II for Triple negative Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands, Italy, Czech Republic, Belgium, USA, France, Spain (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top